Navigation Links
Novelos Therapeutics Presents Diapeutic Technology Platform At EMIT: Targeted Radiotherapy International Conference
Date:1/31/2013

MADISON, Wis., Jan. 31, 2013 /PRNewswire/ -- Novelos Therapeutics, Inc. (OTCQX: NVLT), a pharmaceutical company developing novel drugs for the treatment and diagnosis of cancer, today announced that an oral presentation on research conducted by Novelos and its collaborators is being made by Dr. Christopher Pazoles at the EMIT: Targeted Radiotherapy international conference taking place January 29 to 31, in Washington, D.C.  This presentation by invitation from EMIT describes the mechanistic foundation for Novelos' diapeutic (diagnostic + therapeutic) technology platform together with animal data and initial findings in advanced cancer patients that demonstrate selective and prolonged accumulation of Novelos' PET imaging I-124-CLR1404 (LIGHT), therapeutic I-131-CLR1404 (HOT) and optical imaging CLR1502 (GLOW2) compounds in a range of tumor types.  Dr. Pazoles is the Senior Vice President of Research and Development for Novelos.

"LIGHT, HOT and GLOW2 were designed to exploit a feature shared by most, if not all, cancer cells including cancer stem cells, which results in the selective uptake and prolonged accumulation of our proprietary, small-molecule delivery vehicle in a wide range of malignant tumors compared with normal tissues," said Dr. Pazoles.  "By incorporating a unique functional property in each – PET imaging, radiotherapy or optical imaging – we have generated an array of potential therapeutic and diagnostic products that could, alone or in combinations, significantly improve the detection and treatment of cancer in multiple ways."

Slides of the presentation are available at www.novelos.com/technology-ip/posters-publications/

In his presentation, titled Cancer-Targeted Diapeutics: Radioiodinated Phospholipid Ether Analogs for Broad-Spectrum Imag
'/>"/>

SOURCE Novelos Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
2. Novelos Therapeutics Successfully Completes First Cohort In Phase 1b Solid Tumor Trial With I-131-CLR1404 (HOT) Cancer-Targeted Molecular Radiotherapeutic
3. Novelos Therapeutics Prices $5.4 Million Public Offering
4. Novelos Therapeutics to Present at LHA Life Sciences & Medical Technologies Virtual Conference on June 28
5. Novelos Therapeutics to Present at Rodman & Renshaw 14th Annual Healthcare Conference on September 11
6. Novelos Therapeutics And Academic Collaborators Present Three Posters At 2012 World Molecular Imaging Congress
7. Novelos Therapeutics Successfully Completes Second Cohort In Phase 1b Solid Tumor Trial With I-131-CLR1404 (HOT) Cancer-Targeted Molecular Radiotherapeutic
8. Novelos Therapeutics Announces Enrollment of First Patient in Solid Tumor Imaging Trial with I-124-CLR1404 (LIGHT) Cancer-targeted PET Imaging Agent at UW Carbone Cancer Center
9. Novelos Therapeutics Closes $2 Million Private Placement
10. Novelos Therapeutics To Present At The Benchmark 2012 Micro Cap Discovery Investor Conference On November 29
11. Cell Therapeutics, Inc. (CTI) to Report First Quarter Financial Results on April 20
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... September 22, 2014 Final ... 25   The second edition of the ... excited to announce the final nominations for the 2014 ... on the evening of September 25 at The Taj Mahal Palace, ... applicants based on a variety of qualitative and quantitative ...
(Date:9/22/2014)... Sept. 22, 2014  Elusys Therapeutics, Inc. (Elusys), ... infectious disease, today announced it has completed three ... obiltoxaximab (ETI-204). Obiltoxaximab is an anti-toxin in development ... from these studies support the safety and tolerability ... the intended therapeutic dose. The conclusion of these ...
(Date:9/22/2014)... , Sept. 22, 2014  Aethlon Medical, ... therapeutic devices to address infectious disease, cancer and ... Advanced Research Projects Agency (DARPA) has informed the ... to proceed with year four of a five-year ... on September 30, 2011 under DARPA,s Dialysis-Like Therapeutics ...
Breaking Medicine Technology:Recognising Impactful Healthcare Companies at VCCircle Healthcare Awards 2014 2Recognising Impactful Healthcare Companies at VCCircle Healthcare Awards 2014 3Elusys Announces Results From Three Phase 3 Safety Studies Of Its Anthrax Anti-Toxin, Obiltoxaximab (ETI-204), In Adult Volunteers And Completion Of Its Phase 3 Clinical Development Program 2Elusys Announces Results From Three Phase 3 Safety Studies Of Its Anthrax Anti-Toxin, Obiltoxaximab (ETI-204), In Adult Volunteers And Completion Of Its Phase 3 Clinical Development Program 3Elusys Announces Results From Three Phase 3 Safety Studies Of Its Anthrax Anti-Toxin, Obiltoxaximab (ETI-204), In Adult Volunteers And Completion Of Its Phase 3 Clinical Development Program 4Elusys Announces Results From Three Phase 3 Safety Studies Of Its Anthrax Anti-Toxin, Obiltoxaximab (ETI-204), In Adult Volunteers And Completion Of Its Phase 3 Clinical Development Program 5Elusys Announces Results From Three Phase 3 Safety Studies Of Its Anthrax Anti-Toxin, Obiltoxaximab (ETI-204), In Adult Volunteers And Completion Of Its Phase 3 Clinical Development Program 6Aethlon Medical Receives Notice of DARPA Contract Renewal 2Aethlon Medical Receives Notice of DARPA Contract Renewal 3Aethlon Medical Receives Notice of DARPA Contract Renewal 4
(Date:9/22/2014)... Alan Mozes HealthDay ... Pediatricians, take note: Many American parents are aware of online ... choose a pediatrician for their children, according to a new ... more than 1,600 parents -- further suggest that negative online ... that doctor has been recommended by a neighbor. Conversely, ...
(Date:9/22/2014)... a whole eye transplant seems futuristic, if not ... U.S. Department of Defense, researchers at University of ... someday make implantation of an entire, functional eye ... be a holy grail for vision restoration," said ... grant co-recipient with colleagues at University of Pittsburg ...
(Date:9/22/2014)... have found that an anticonvulsant drug may help in ... dozens of antibiotics target what bacteria do, their study ... are created, and they found there is a way ... as there is growing concern worldwide about how antibiotic ... World Health Organization has declared that antibiotic resistance is ...
(Date:9/22/2014)... 22, 2014 An inventor and anesthesiologist ... the problem of side-sleeping. "My lower arm always became ... designed a solution to this problem," she said. "It’s ... to have your arm 'fall asleep.'" , The Sleeping ... her side more comfortably. It avoids pain and restlessness ...
(Date:9/22/2014)... 2014 -- Recent two-generation approaches to reducing poverty ... increasing attention from researchers, advocates, and foundations. By ... them to move to jobs that offer a ... and education for children, these programs aim to ... according to a new report from the National ...
Breaking Medicine News(10 mins):Health News:Many Parents Use Online Ratings to Pick a Pediatrician, Study Finds 2Health News:Many Parents Use Online Ratings to Pick a Pediatrician, Study Finds 3Health News:Looking ahead: Whole eye transplant under development 2Health News:A two-generation lens: Current state policies fail to support families with young children 2
... WashingtonThe American College of Physicians (ACP) today applauded Rep. ... for their bipartisan introduction of the Medicare Physician Payment ... is designed to eliminate the flawed Sustainable Growth Rate ... scheduled cuts. The SGR cuts threaten to drive physicians ...
... Black Americans who suffer cardiac arrest in public places are ... automated external defibrillators, a new study has found. Cardiac ... to stop beating. CPR and automated external defibrillators (AEDs) -- ... a normal rhythm -- can help a cardiac arrest victim ...
... May 11 (HealthDay News) -- Heart attack survivors are more ... it,s safe, a new study shows. University of Chicago ... study. Among patients who were sexually active before their heart ... discharged from the hospital were 1.5 times more likely to ...
... Brophy Marcus HealthDay Reporter , FRIDAY, May ... their periods, but new research suggests weight-loss surgery can ... hair growth and skin problems that often accompany significant ... the United States," said study author Chandhana Paka, a ...
... mobility now have access to specialized exercise equipment in ... the University of Alberta and the Spinal Cord Injury ... electrical stimulation (FES) rehabilitation therapy machines are now available ... Faculty of Physical Education and Recreation at the U ...
... disease allow physicians to tailor treatment to a patient,s ... many types of cancer the molecular subtypes are more ... that can affect a patient,s response to therapy. ... the first time that lung cancer molecular subtypes correlate ...
Cached Medicine News:Health News:ACP applauds introduction of bipartisan bill to eliminate Medicare SGR formula 2Health News:Blacks Less Likely to Get Help on Scene After Cardiac Arrest: Study 2Health News:Blacks Less Likely to Get Help on Scene After Cardiac Arrest: Study 3Health News:Sex After Heart Attack? Doc's OK May Be Key 2Health News:Weight-Loss Surgery May Also Help Menstruation, Skin, Hair 2Health News:Weight-Loss Surgery May Also Help Menstruation, Skin, Hair 3Health News:Partnership provides inclusive workout 2Health News:Partnership provides inclusive workout 3Health News:Molecular subtypes and genetic alterations may determine response to lung cancer therapy 2
... innovative stent allows the physician to intubate the ... with just topical anesthetic drops., ,The SRS is ... in three lengths 25mm, 30mm and 35mm (disposable ... stent is an anchor-shaped head to provide fixation. ...
... or somatomedin-C, is a peptide highly dependent ... promoting activity. IGF-I is transported in serum ... of growth disorders, measurements of IGF-I are ... hormone secretion. A normal plasma or serum ...
... is a high-throughput immunoassay system built around ... 2000 with the important addition of Logic ... to be designed for optimal performance with ... for critical assays such as the cardiac ...
... For The Detection ... Uses Of C-Peptide Measurement:, ... fasting hypoglycemia , Assisting ... diabetes mellitus , Differentiating ...
Medicine Products: